Navigation Links
Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
Date:2/28/2008

the Company's largest single category of generic products, were $118 million for the fourth quarter of 2007, compared to $114 million in the prior year period. The Company launched its 25th generic oral contraceptive product, TriLegest(TM) during the fourth quarter of 2007.

Europe and Rest of the World ("ROW") Generic Sales

Sales of generic products in Europe and the ROW through our PLIVA subsidiary were $196 million in the fourth quarter of 2007. Revenues were primarily driven by sales of PLIVA products in the key markets of Germany, Croatia, Poland and Russia. Prior to the Company's acquisition of PLIVA in October 2006, Barr did not have any product sales in Europe or the ROW.

Proprietary Product Sales

The Company's proprietary product sales were $438 million for 2007, up 12% compared to $391 million in 2006. The increase was primarily attributable to higher sales of Plan B Over-the-Counter/Rx, Adderall(R) IR and SEASONIQUE(R) extended-cycle oral contraceptive, all of which were launched in the second half of 2006. These increases more than offset lower sales of SEASONALE(R) extended-cycle oral contraceptive, which faced generic competition in September 2006 following the expiration of three years of market exclusivity.

For the fourth quarter of 2007, proprietary product sales were $122 million, compared to $98 million in the prior year period. The increase was primarily attributable to higher sales of Plan B and SEASONIQUE and more than offset the expected lower sales of SEASONALE.

Alliance and Development Revenue

During 2007, the Company reported alliance and development revenue of $122 million, compared to $131 million in 2006. For the fourth quarter of 2007, alliance and development revenue was $28 million, as compared to $34 million in the prior year period. The decrease for the year and for the fourth quarter ended December 31, 2007 primarily reflects a decline in income derived from the Company's share of the
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. QMed, Inc. Reports July Medicare SNP Enrollments
3. Phlo Affiliate Reports Expanded Coverage to Oregon Border
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
6. Carrington Reports Second Quarter 2007 Results
7. Avitar Reports Third Quarter Financial Results for Fiscal 2007
8. Response Genetics Reports Second Quarter 2007 Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
10. Transgenomic, Inc. Reports Second Quarter 2007 Results
11. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Shimadzu Scientific Instruments today ... UV-visible spectrophotometer. Offering wavelength scanning from 190 to ... for applications in a variety of industries, including ... user-friendly UV-1280 enables intuitive operation, while the enhanced ...
(Date:1/22/2015)... 2015  Transwestern | RBJ today announces the firm brokered a ... Shire a leading biopharmaceutical company, at Two Ledgemont Center in ... Robert Richards , president, and Brian Cohen , senior ... five-floor building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to the ... consultants, Protocol Networks has recently announced its expansion into ... his company has attracted several clients in The Constitution ... as others. With the success of these engagements, Rogers ...
(Date:1/22/2015)... zFlo Motion , a US leader ... exciting product from a new partner. STT-Systems has ... past 15 years, with offerings in the optical-motion capture, 3D ... system (inertial measurement unit), iSen, is opening eyes around the ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2
... Wis. - The Fitchburg Plan Commission has recommended approval ... building and data center that would accommodate the expansion of ... the anchor tenant in both buildings, which are planned for ... Fitchburg Technology Campus . , ,The plans, which now go ...
... hero, she was heading to the tiny island nation of ... Indian Ocean. By all reports and expectations, she would be off ... disconnection. , ,Or maybe not. After 36 hours in ... made our way through customs and out into the humid night ...
... - Tanya Townsend didn't have much time to pass the ... many other information technology directors have an opportunity to start ... and new processes? , ,Not many, and when the ... shopping for a chief technology executive in 2004, Townsend beat ...
Cached Biology Technology:Berbee to expand at New Venture Center 2Coveted vacation "disconnect" was elusive 2Coveted vacation "disconnect" was elusive 3CIO Leadership Series: Tanya Townsend, Saint Clare's Hospital 2CIO Leadership Series: Tanya Townsend, Saint Clare's Hospital 3CIO Leadership Series: Tanya Townsend, Saint Clare's Hospital 4CIO Leadership Series: Tanya Townsend, Saint Clare's Hospital 5
(Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced today its ... confirm its adherence to current U.S. Food and Drug ... regulated smart device and smart phone application trials utilizing ... "HITLAB is determined to improve global healthcare ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... the power of 21st century computing to confirm an idea ... cycles evolve faster. Their findings appear in the October 3rd ... consequence for the understanding of evolution made possible by the ... said senior author Michael Donoghue , the G. Evelyn ...
... Using computer models and live cell experiments, biomedical engineers at ... than 100 human protein fragments that can slow or stop ... Reporting online last week in the Proceedings ... the findings could lead to developing treatments to fight diseases ...
... has confirmed the appointment of Esin Gulari, dean of the ... on the National Science Board (NSB). President George W. Bush ... scientists. "This is a tremendous honor for me as ... I will be in a unique position to make contributions ...
Cached Biology News:Reproducing early and often is the key to rapid evolution in plants 2Discovery of natural compounds that could slow blood vessel growth 2US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board 2
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
One-step, colorimetric, linear detection range 0.7 mg/dL to 300 mg/dL. Procedure: 10 min....
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Recombinant Mouse LIGHT/TNFSF14...
Biology Products: